Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Mydriacyl Ophthalmic Product

PreclinicalSmall molecule

MMantis Photonics AB

Mydriacyl Ophthalmic Product is one of 2 small molecule programs targeting Oxygenation. It is currently in Preclinical.

1

Indications

1

Total Trials

0

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

OxygenationUnknown status

OxygenationPreclinical

Unknown status

Competition

Competitive Landscape

3 competitors in Oxygenation

#DrugCompanyPhaseTrials

NORADRENALIN

UUniversity of Aarhus

Mydriacyl Ophthalmic Product

MMantis Photonics AB

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Oxygenation1 trial

Retinal Oxygenation Estimation Trial With Mantis Photonics Hyperspectral Camera

Unknown status·MMantis Photonics AB·N/A·NCT05566626·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Mydriacyl Ophthalmic Product. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mydriacyl Ophthalmic Product compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mydriacyl Ophthalmic Product. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mantis Photonics AB company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMantis Photonics AB

Related News